Groundbreaking diabetes technology

We deliver the next generation intelligence for insulin pumps, smart pens and other medical devices to make diabetes care smarter, more reliable, more accurate, and more reassuring than ever before.

Our ambition: Peace of mind

Improve the life of people with diabetes

Our ambition is to provide people with diabetes with as much peace of mind, serenity and foresight as possible, so that they can experience their daily lives in a relaxed manner without interruptions – even in stressful, strenuous or unusual situations.

...with the newest ML technology

We applied the newest machine learning technology to millions of datasets to develop the smartest and most accurate diabetes care algorithm: bioX®. It turns raw health data into contextualized biomarkers and impactful predictions, while constantly evolving its understanding of the individual’s body and behaviour. It manages the precise insulin requirements of a person with diabetes and controls insulin delivery by insulin pumps or smart pens with the highest precision.

What is so unique about OneTwenty?

More accurate than any other solution

Through the reliable and transparent calculation of previously unused factors and technologies, bioX® achieves a previously impossible clinically-safe prediction accuracy.

Future-proof technology approach

bioX® applies the latest technology, which was hidden from previous solutions, and is therefore investment-proof in the long term.

High integration capability

bioX® integrates easily into existing medical products and their controls due to its extremely small hardware footprint. For new product developments, we work closely with the partner and help with the ideal hardware-software integration.

Developed together with the community

Through countless interactions and in numerous workshops, we developed and refined the solution not for but with people with diabetes, so that bioX® ends up helping users exactly as they need it, and exactly when they need it.

Beyond medication based treatment

bioX® not only controls medication for people with diabetes, but also helps in everyday life to optimize one's own lifestyle even better for a more relaxed life.

Ready to speak with OneTwenty?

Interested in our solution?

We are happy to present the details of our solutions and discuss possible cooperation. Just contact us via LinkedIn or via eMail:  

inquiries@onetwenty.ai

Interested in an interview?

We are available to journalists, bloggers and editors for background discussions and interviews. Just contact us via Linkedin or write to us by eMail at 

multipliers@onetwenty.ai

Proven by millions of real data

Built, tuned and tested with 4.4 million CGM hours collected in clinical trials, as well as from in-silico subjects, and collected within our own protocol from open-loop and closed-loop-therapy.

Approved by innovative diabetes tech companies

First medtech companies already work with OneTwenty and integrate bioX in their solutions

Ready for joint improvements

Due to the flexibility and modern architecture of bioX we are open for joint improvements, inputs and optimizations on existing hardware systems

Reliable Swiss quality

bioX was developed in Switzerland by medical and machine learning professionals and optimized in collaboration with a recognized professor in this field.

Attractive licensing model

The integration and use of bioX is facilitated by an attractive and flexible licensing model that allows you to pay only for what you use.

What can bioX be applied for?

Glucoregulatory Solution

bioX is learning the individual reactions, patterns and hidden dependencies of glucose reactions and insulin regulation to build a synthetic glucoregulatory model that imitates a natural, non-impaired system in the most accurate way. The result: bioX precisely and reliably manages the insulin dosing of pumps and pens. We call it: bioX neoAP & medicAID

Biomarker Prediction

bioX predicts specific biomarker values, patient reported outcomes (PROs) and health impacting events based on personalized health data through Deep Learning and helps users understand their metabolism and change their lifestyle. We call it: bioX healthAID

Sensor Optimization

bioX leverages ML to build highly optimized algorithms for data translation from raw sensor data into the target biomarker, such as glucose levels, ketones or fertility scoring, on a groundbreaking accuracy. That way we are able to make sensors more reliable, more accurate and applicable to even more areas. We call it: bioX sensAI

Proven performance, successful application

bioX for insulin pumps:
50% more Time-in-Range through learning-closed-loop solution

bioX improved the Time-in-Range performance of a hybrid-closed-loop system (HCL AID) by 50%. First new products that will be based on bioX are currently in development with pump providers and will be released to the market after clinical trials and regulatory processes are finished. 

bioX for sensors:
65% more accurate non-invasive sensor data

bioX has been applied for a non-invasive CGM and has been tested with datasets previously unseen by the model during training, exclusively with sensor data and reference blood glucose data. The sensor data accuracy increased by 65% compared to the performance of the existing algorithm, even outperforming most invasive CGMs in accuracy.

Want to speak with us now?

About our solution?

We are happy to present the details of our solutions and discuss possible cooperation. Just contact us via LinkedIn or via eMail:  

inquiries@onetwenty.ai

About an interview?

We are available to journalists, bloggers and editors for background discussions and interviews. Just contact us via LinkedIn or write to us by eMail at 

multipliers@onetwenty.ai

OneTwenty - a fresh company combining research, newest technology and real life experience

Inspired by our passion for people’s health, we are dedicated to improving lives and giving the gift of a self-owned life. With OneTwenty we want to help >500m people with diabetes to avoid the impact of their disease or reverse the disease completely. We want to give peace-of-mind to people with diabetes globally.

A founding team rooted in technology, medicine & digital products

Dr. med. Julian Stiels

CTO, Medical Strategist

Medical doctor, serial entrepreneur with track record in machine learning apps, co-founder of Uplyfe.io

Michael Rottmann

CEO, investor

Serial entrepreneur, co-founder of Uplyfe.io, 20y experience in digital products & B2B account management

Backed by dynamic & acknowledged advisors

Nicole Büttner
Founder & CEO of Merantix Momentum, WEF Digital Leader for Europe, recognized expert in artificial intelligence and company formation, supervisory board member in various companies, investor, economist
Fredrik Debong
Cofounder and chair of hi.health, cofounder of mySugr.com, pioneers.io
Florence Barkats
Digital Health Tech Innovation Advisor, Patient advocate, Head of Clinical Services Philips (UK), Lay Member NHS Improvement (UK)

Dr. med. Anne Sophie Kubasch

Research Group Leader and Clinician Scientist, Artificial Intelligence (AI) in Hematology, Department of Hematology, Cellular Therapy and Hemostaseology, University Hospital Leipzig

Our partners

Last chance to speak with us!

Want to know more about our solution?

We are happy to present the details of bioX and discuss a possible cooperation. Just contact us via LinkedIn or eMail: 
inquiries@onetwenty.ai

Want to conduct an interview with us?

We are available to journalists, bloggers and editors for background discussions and interviews. Just contact us via LinkedIn or write to us by eMail: 
multipliers@onetwenty.ai

Ready to take your diabetes care to the next level?

Get In Touch

Company

Service & Resources

  • Whitepaper (soon)
  • FAQ (Soon)
  • Publications (soon)

© Copyright 2024 OneTwenty AG, All rights reserved.

¹ PMID: 19254969; https://doi.org/10.1155/2020/1834534; https://doi.org/10.1007/s00125-021-05396-5; PMID: 26649106; PMID: 34790639
² https://doi.org/10.1002/edm2.379; https://doi.org/10.2337/dci21-0043; 12 week measurements compared to study baselines
³ Reported time <50mg/dL across all subjects over 12 weeks: average of 0.78% and median of 0.21% time spent in hypoglycemia
⁴ ML prediction up to a 120 minute horizon and accuracy per point measurement at 76.8% ±4.2% 

bioX is an investigational solution limited by Swiss law to investigational use. Not available for sale. To be clear, bioX is not yet commercially available because it has not yet been cleared by the MDR or FDA or any other regulatory body. We will have to obtain regulatory clearances before we can offer it for commercial sale.

OneTwenty and bioX are registered trademarks of OneTwenty AG. Other trademarks are the property of their respective owners. No use of any OneTwenty AG trademark, trade name, or trade dress in this site may be made without the prior written authorisation of OneTwenty AG, except to identify the product or services of the company. The product images are for illustrative purposes only.